Oncolytic measles viruses for cancer therapy

Expert Opinion on Biological Therapy

Volumn 4, Issue 10, 2004, Pages 1685-1692

  Nakamura, Takafumi ^a   Russell, Stephen J ^a  

^a Mayo Clinic   (United States)

Author keywords

Cancer; Oncolytic measles virus; Virotherapy

Indexed keywords

CD150 ANTIGEN; ONCOLYTIC VIRUS; VIRUS VECTOR;

ANTINEOPLASTIC ACTIVITY; CANCER; CANCER MODEL; CANCER THERAPY; CELL DEATH; CELL FUSION; EDMONSTON B MEASLES VACCINE STRAIN; GENETIC ENGINEERING; HUMAN; IMMUNE RESPONSE; MEASLES VIRUS; NONHUMAN; REVIEW; SAFETY; TUMOR CELL DESTRUCTION; VIRUS CELL INTERACTION; VIRUS INFECTIVITY; VIRUS REPLICATION; VIRUS STRAIN;

ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, CD; ANTIGENS, CD46; DEFECTIVE VIRUSES; DENDRITIC CELLS; GENETIC ENGINEERING; GLYCOPROTEINS; HUMANS; IMMUNOGLOBULINS; MEASLES VIRUS; MICE; MICE, TRANSGENIC; NEOPLASMS; ONCOLYTIC VIROTHERAPY; PRIMATES; RECEPTORS, CELL SURFACE; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MEASLES VIRUS;

EID: 5644237829     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.4.10.1685     Document Type: Review

References (65)

1. KIRN D, MARTUZA RL, ZWIEBEL J: Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat. Med. (2001) 7(7):781-787.
2. RUSSELL SJ: RNA viruses as virotherapy agents. Cancer Gene Ther. (2002) 9(12):961-966.
3. GRIFFIN DE: Measles virus. In: Fields Virology. Knipe DM, Howley PM (Eds), Lippincott Williams & Wilkins, Philadelphia, USA (2001):1402-1442.
4. CATHOMEN T, NAIM HY, CATTANEO R: Measles viruses with altered envelope protein cytoplasmic tails gain cell fusion competence. J. Virol. (1998) 72(2):1224-1234.
5. WILD TF, FAYOLLE J, BEAUVERGER P, BUCKLAND R: Measles virus fusion: role of the cysteine-rich region of the fusion glycoprotein. J. Virol. (1994) 68(11):7546-7548.
6. DORIG RE, MARCIL A, CHOPRA A, RICHARDSON CD: The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell (1993) 75(2):295-305.
7. NANICHE D, VARIOR-KRISHNAN G, CERVONI F et al.: Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus. J. Virol. (1993) 67(10):6025-6032.
8. TATSUO H, ONO N, TANAKA K, YANAGI Y: SLAM (CDw150) is a cellular receptor for measles virus. Nature (2000) 406(6798):893-897.
9. HSU EC, IORIO C, SARANGI F, KHINE AA, RICHARDSON CD: CDw150(SLAM) is a receptor for a lymphotropic strain of measles virus and may account for the immunosuppressive properties of this virus. Virology (2001) 279(1):9-21.
10. MINAGAWA H, TANAKA K, ONO N, TATSUO H, YANAGI Y: Induction of the measles virus receptor SLAM (CD150) on monocytes. J. Gen. Virol. (2001) 82(Pt 12):2913-2917.
11. OLDSTONE MB: Measles virus. In: Viruses, Plagues and History. Oldstone MB (Ed.), Oxford Press, New York, USA (1998).
12. CUTTS FT, MARKOWITZ LE: Successes and failures in measles control. J. Infect. Dis. (1994) 170(Suppl. 1):S32-S41.
13. BLUMING AZ, ZIEGLER JL: Regression of Burkitt's lymphoma in association with measles infection. Lancet (1971) 2(7715):105-106.
14. PENG KW, AHMANN GJ, PHAM L et al.: Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood (2001) 98(7):2002-2007.
15. PENG KW, TENEYCK CJ, GALANIS E et al.: Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res. (2002) 62(16):4656-4662.
16. GROTE D, RUSSELL SJ, CORNU TI et al.: Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. Blood (2001) 97(12):3746-3754.
17. PHUONG LK, ALLEN C, PENG KW et al.: Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Cancer Res. (2003) 63(10):2462-2469.
18. YANAGI Y: The cellular receptor for measles virus-elusive no more. Rev. Med. Virol. (2001) 11(3):149-156.
19. SCHNEIDER U, VON MESSLING V, DEVAUX P, CATTANEO R: Efficiency of measles virus entry and dissemination through different receptors. J. Virol. (2002) 76(15):7460-7467.
20. HSU EC, SARANGI F, IORIO C et al.: A single amino acid change in the hemagglutinin protein of measles virus determines its ability to bind CD46 and reveals another receptor on marmoset B cells. J. Virol. (1998) 72(4):2905-2916.
21. JURIANZ K, ZIEGLER S, GARCIA-SCHULER H et al.: Complement resistance of tumor cells: basal and induced mechanisms. Mol. Immunol. (1999) 36(13-14):929-939.
22. SANTIAGO C, BJORLING E, STEHLE T, CASASNOVAS JM: Distinct kinetics for binding of the CD46 and SLAM receptors to overlapping sites in the measles virus hemagglutinin protein. J. Biol. Chem. (2002) 277(35):32294-32301.
23. ANDERSON BD, NAKAMURA T, RUSSELL SJ, PENG KW: High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Res. (2004) 64(14):4919-4926.
24. KATZE MG, HE Y, GALE M JR: Viruses and interferon: a fight for supremacy. Nat. Rev. Immunol. (2002) 2(9):675-687.
25. STOJDL DF, LICHTY BD, TENOEVER BR et al.: VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell (2003) 4(4):263-275.
26. BALACHANDRAN S, BARBER GN: Vesicular stomatitis virus (VSV) therapy of tumors. IUBMB Life (2000) 50(2):135-138.
27. STRONG JE, COFFEY MC, TANG D, SABININ P, LEE PW: The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J. (1998) 17(12):3351-3362.
28. NORMAN KL, LEE PW: Reovirus as a novel oncolytic agent. J. Clin. Invest. (2000) 105(8):1035-1038.
29. FARASSATI F, YANG AD, LEE PW: Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1. Nat. Cell Biol. (2001) 3(8):745-750.
30. VARGHESE S, RABKIN SD: Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther. (2002) 9(12):967-978.
31. DINGLI D, PENG KW, HARVEY ME et al.: Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood (2004) 103(5):1641-1646.
32. SPITZWEG C, ZHANG S, BERGERT ER et al.: Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines. Cancer Res. (1999) 59(9):2136-2141.
33. CHO JY, SHEN DH, YANG W et al.: In vivo imaging and radioiodine therapy following sodium iodide symporter gene transfer in animal model of intracerebral gliomas. Gene Ther. (2002) 9(17):1139-1145.
34. SIMPKIN DJ, MACKIE TR: EGS4 Monte Carlo determination of the beta dose kernel in water. Med. Phys. (1990) 17(2):179-186.
35. BRAMSON JL, HITT M, ADDISON CL et al.: Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12. Hum. Gene Ther. (1996) 7(16):1995-2002.
36. ANDREANSKY S, HE B, VAN COTT J et al.: Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins. Gene Ther. (1998) 5(1):121-130.
37. D'ANGELICA M, KARPOFF H, HALTERMAN M et al.: In vivo interleukin-2 gene therapy of established tumors with herpes simplex amplicon vectors. Cancer Immunol. Immunother. (1999) 47(5):265-271.
38. KUTUBUDDIN M, FEDEROFF HJ, CHALLITA-EID PM et al.: Eradication of pre-established lymphoma using herpes simplex virus amplicon vectors. Blood (1999) 93(2):643-654.
39. TRUDEL S, TRACHTENBERG J, TOI A et al.: A Phase I trial of adenovector-mediated delivery of interleukin-2 (AdIL-2) in high-risk localized prostate cancer. Cancer Gene Ther. (2003) 10(10):755-763.
40. WONG RJ, PATEL SG, KIM S et al.: Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma. Hum. Gene Ther. (2001) 12(3):253-265.
41. GROTE D, CATTANEO R, FIELDING AK: Neutrophils contribute to the measles virus-induced antitumor effect: enhancement by granulocyte macrophage colony-stimulating factor expression. Cancer Res. (2003) 63(19):6463-6468.
42. PENG KW, FACTEAU S, WEGMAN T, O'KANE D, RUSSELL SJ: Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides. Nat. Med. (2002) 8(5):527-531.
43. AUWAERTER PG, ROTA PA, ELKINS WR et al.: Measles virus infection in rhesus macaques: altered immune responses and comparison of the virulence of six different virus strains. J. Infect. Dis. (1999) 180(4):950-958.
44. HSU EC, DORIG RE, SARANGI F et al.: Artificial mutations and natural variations in the CD46 molecules from human and monkey cells define regions important for measles virus binding. J. Virol. (1997) 71(8):6144-6154.
45. KEMPER C, LEUNG M, STEPHENSEN CB et al.: Membrane cofactor protein (MCP; CD46) expression in transgenic mice. Clin. Exp. Immunol. (2001) 124(2):180-189.
46. MANCHESTER M, RALL GF: Model systems: transgenic mouse models for measles pathogenesis. Trends Microbiol. (2001) 9(1):19-23.
47. OLDSTONE MB, LEWICKI H, THOMAS D et al.: Measles virus infection in a transgenic model: virus-induced immunosuppression and central nervous system disease. Cell (1999) 98(5):629-640.
48. HAHM B, ARBOUR N, NANICHE D et al.: Measles virus infects and suppresses proliferation of T lymphocytes from transgenic mice bearing human signaling lymphocytic activation molecule. J. Virol. (2003) 77(6):3505-3515.
49. MRKIC B, PAVLOVIC J, RULICKE T et al.: Measles virus spread and pathogenesis in genetically modified mice. J. Virol. (1998) 72(9):7420-7427.
50. MRKIC B, ODERMATT B, KLEIN MA et al.: Lymphatic dissemination and comparative pathology of recombinant measles viruses in genetically modified mice. J. Virol. (2000) 74(3):1364-1372.
51. ROSCIC-MRKIC B, SCHWENDENER RA, ODERMATT B et al.: Roles of macrophages in measles virus infection of genetically modified mice. J. Virol. (2001) 75(7):3343-3351.
52. PENG KW, FRENZKE M, MYERS R et al.: Biodistribution of oncolytic measles virus after intraperitoneal administration into Ifnar™-CD46Ge transgenic mice. Hum. Gene Ther. (2003) 14(16):1565-1577.
53. SCHNEIDER-SCHAULIES S, BIEBACK K, AVOTA E, KLAGGE I, TER MEULEN V: Regulation of gene expression in lymphocytes and antigen-presenting cells by measles virus: consequences for immunomodulation. J. Mol. Med. (2002) 80(2):73-85.
54. MCQUAID S, COSBY SL: An immunohistochemical study of the distribution of the measles virus receptors, CD46 and SLAM, in normal human tissues and subacute sclerosing panencephalitis. Lab. Invest. (2002) 82(4):403-409.
55. KLAGGE IM, TER MEULEN V, SCHNEIDER-SCHAULIES S: Measles virus-induced promotion of dendritic cell maturation by soluble mediators does not overcome the immunosuppressive activity of viral glycoproteins on the cell surface. Eur. J. Immunol. (2000) 30(10):2741-2750.
56. SCHNEIDER U, BULLOUGH F, VONGPUNSAWAD S, RUSSELL SJ, CATTANEO R: Recombinant measles viruses efficiently entering cells through targeted receptors. J. Virol. (2000) 74(21):9928-9936.
57. HAMMOND AL, PLEMPER RK, ZHANG J et al.: Single-chain antibody displayed on a recombinant measles virus confers entry through the tumor-associated carcinoembryonic antigen. J. Virol. (2001) 75(5):2087-2096.
58. PENG KW, DONOVAN KA, SCHNEIDER U et al.: Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker. Blood (2003) 101(7):2557-2562.
59. BUCHEIT AD, KUMAR S, GROTE DM et al.: An oncolytic measles virus engineered to enter cells through the CD20 antigen. Mol. Ther. (2003) 7(1):62-72.
60. PENG KW, HOLLER P, ORR B, KRANZ DM, RUSSELL SJ: Targeting virus entry and membrane fusion through specific peptide/MHC complexes using a high-affinity T-cell receptor. Gene Ther. (2004) 11(15):1234-1239.
61. LECOUTURIER V, FAYOLLE J, CABALLERO M et al.: Identification of two amino acids in the hemagglutinin glycoprotein of measles virus (MV) that govern hemadsorption, HeLa cell fusion, and CD46 downregulation: phenotypic markers that differentiate vaccine and wild-type MV strains. J. Virol. (1996) 70(7):4200-4204.
62. PATTERSON JB, SCHEIFLINGER F, MANCHESTER M, YILMA T, OLDSTONE MB: Structural and functional studies of the measles virus hemagglutinin: identification of a novel site required for CD46 interaction. Virology (1999) 256(1):142-151.
63. MASSE N, BARRETT T, MULLER CP, WILD TF, BUCKLAND R: Identification of a second major site for CD46 binding in the hemagglutinin protein from a laboratory strain of measles virus (MV): potential consequences for wild-type MV infection. J. Virol. (2002) 76(24):13034-13038.
64. VONGPUNSAWAD S, OEZGUN N, BRAUN W, CATTANEO R: Selectively receptor-blind measles viruses: identification of residues necessary for SLAM- or CD46-induced fusion and their localization on a new hemagglutinin structural model. J. Virol. (2004) 78(1):302-313.
65. NAKAMURA T, PENG KW, VONGPUNSAWAD S et al.: Antibody-targeted cell fusion. Nat. Biotechnol. (2004) 22(3):331-336.